APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biologics CDMO Market Outlook and Growth Opportunities 2026

30 December 2025193 pages

Choose your research edition.

Industry ResearchBiologics CDMO Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics CDMO Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Biologics CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics CDMO Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics CDMO Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Biologics CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biologics CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biologics CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologics CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biologics CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biologics CDMO market include AGC, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, ICON Plc, Samsung Biologics, Toyobo, AbbVie, Lonza Group AG and Thermo Fisher Scientific, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Biologics CDMO market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologics CDMO and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologics CDMO sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biologics CDMO market size, projected growth trends, production technologies, key applications, and end-use industries.

Biologics CDMO Segment by Company

AGC

Boehringer Ingelheim

Fujifilm Diosynth Biotechnologies

ICON Plc

Samsung Biologics

Toyobo

AbbVie

Lonza Group AG

Thermo Fisher Scientific

WuXi Biologics

Biologics CDMO Segment by Type

Biological Agent

Biosimilar Drug

Biologics CDMO Segment by Application

Cell Therapy

Drug Development

Others

Biologics CDMO Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Biologics CDMO status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Biologics CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biologics CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Biologics CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologics CDMO market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics CDMO industry.

Chapter 3: Detailed analysis of Biologics CDMO manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Biologics CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Biologics CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biologics CDMO Industry Trends Table 2. Biologics CDMO Industry Drivers Table 3. Biologics CDMO Industry Opportunities and Challenges Table 4. Biologics CDMO Industry Restraints Table 5. Global Biologics CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biologics CDMO Revenue Share by Company (2021-2026) Table 7. Global Biologics CDMO Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Biologics CDMO Sales Volume Share by Company (2021-2026) Table 9. Global Biologics CDMO Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Biologics CDMO Company Ranking, (2024-2026) & (USD Million) Table 11. Global Biologics CDMO Key Company Manufacturing Base & Headquarters Table 12. Global Biologics CDMO Company, Product Type & Application Table 13. Global Biologics CDMO Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Biologics CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Biological Agent Table 18. Significant Companies of Biosimilar Drug Table 19. Global Biologics CDMO Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Biologics CDMO Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Biologics CDMO Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Biologics CDMO Sales Volume Share by Type (2021-2026) Table 23. Global Biologics CDMO Sales Volume Share by Type (2027-2032) Table 24. Global Biologics CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Biologics CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Biologics CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Biologics CDMO Sales Value Share by Type (2021-2026) Table 28. Global Biologics CDMO Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Cell Therapy Table 30. Significant Companies of Drug Development Table 31. Significant Companies of Others Table 32. Global Biologics CDMO Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Biologics CDMO Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Biologics CDMO Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Biologics CDMO Sales Volume Share by Application (2021-2026) Table 36. Global Biologics CDMO Sales Volume Share by Application (2027-2032) Table 37. Global Biologics CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Biologics CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Biologics CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Biologics CDMO Sales Value Share by Application (2021-2026) Table 41. Global Biologics CDMO Sales Value Share by Application (2027-2032) Table 42. Global Biologics CDMO Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Biologics CDMO Sales by Region (2021-2026) & (K Units) Table 44. Global Biologics CDMO Sales Market Share by Region (2021-2026) Table 45. Global Biologics CDMO Sales by Region (2027-2032) & (K Units) Table 46. Global Biologics CDMO Sales Market Share by Region (2027-2032) Table 47. Global Biologics CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Biologics CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Biologics CDMO Sales Value Share by Region (2021-2026) Table 50. Global Biologics CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Biologics CDMO Sales Value Share by Region (2027-2032) Table 52. Global Biologics CDMO Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Biologics CDMO Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Biologics CDMO Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Biologics CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 57. Global Biologics CDMO Sales Market Share by Country (2021-2026) Table 58. Global Biologics CDMO Sales by Country (2027-2032) & (K Units) Table 59. Global Biologics CDMO Sales Market Share by Country (2027-2032) Table 60. Global Biologics CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Biologics CDMO Sales Value Market Share by Country (2021-2026) Table 62. Global Biologics CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Biologics CDMO Sales Value Market Share by Country (2027-2032) Table 64. AGC Company Information Table 65. AGC Business Overview Table 66. AGC Biologics CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. AGC Biologics CDMO Product Portfolio Table 68. AGC Recent Development Table 69. Boehringer Ingelheim Company Information Table 70. Boehringer Ingelheim Business Overview Table 71. Boehringer Ingelheim Biologics CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Boehringer Ingelheim Biologics CDMO Product Portfolio Table 73. Boehringer Ingelheim Recent Development Table 74. Fujifilm Diosynth Biotechnologies Company Information Table 75. Fujifilm Diosynth Biotechnologies Business Overview Table 76. Fujifilm Diosynth Biotechnologies Biologics CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Fujifilm Diosynth Biotechnologies Biologics CDMO Product Portfolio Table 78. Fujifilm Diosynth Biotechnologies Recent Development Table 79. ICON Plc Company Information Table 80. ICON Plc Business Overview Table 81. ICON Plc Biologics CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. ICON Plc Biologics CDMO Product Portfolio Table 83. ICON Plc Recent Development Table 84. Samsung Biologics Company Information Table 85. Samsung Biologics Business Overview Table 86. Samsung Biologics Biologics CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Samsung Biologics Biologics CDMO Product Portfolio Table 88. Samsung Biologics Recent Development Table 89. Toyobo Company Information Table 90. Toyobo Business Overview Table 91. Toyobo Biologics CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Toyobo Biologics CDMO Product Portfolio Table 93. Toyobo Recent Development Table 94. AbbVie Company Information Table 95. AbbVie Business Overview Table 96. AbbVie Biologics CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. AbbVie Biologics CDMO Product Portfolio Table 98. AbbVie Recent Development Table 99. Lonza Group AG Company Information Table 100. Lonza Group AG Business Overview Table 101. Lonza Group AG Biologics CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Lonza Group AG Biologics CDMO Product Portfolio Table 103. Lonza Group AG Recent Development Table 104. Thermo Fisher Scientific Company Information Table 105. Thermo Fisher Scientific Business Overview Table 106. Thermo Fisher Scientific Biologics CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Thermo Fisher Scientific Biologics CDMO Product Portfolio Table 108. Thermo Fisher Scientific Recent Development Table 109. WuXi Biologics Company Information Table 110. WuXi Biologics Business Overview Table 111. WuXi Biologics Biologics CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. WuXi Biologics Biologics CDMO Product Portfolio Table 113. WuXi Biologics Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Biologics CDMO Distributors List Table 117. Biologics CDMO Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Biologics CDMO Product Image Figure 2. Global Biologics CDMO Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics CDMO Sales Value (2021-2032) & (US$ Million) Figure 4. Global Biologics CDMO Sales (2021-2032) & (K Units) Figure 5. Global Biologics CDMO Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Biologics CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Biological Agent Image Figure 10. Biosimilar Drug Image Figure 11. Global Biologics CDMO Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Biologics CDMO Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Biologics CDMO Sales Volume Share by Type (2021-2032) Figure 14. Global Biologics CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Biologics CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Biologics CDMO Sales Value Share by Type (2021-2032) Figure 17. Cell Therapy Image Figure 18. Drug Development Image Figure 19. Others Image Figure 20. Global Biologics CDMO Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Biologics CDMO Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Biologics CDMO Sales Volume Share by Application (2021-2032) Figure 23. Global Biologics CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Biologics CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Biologics CDMO Sales Value Share by Application (2021-2032) Figure 26. Global Biologics CDMO Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Biologics CDMO Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Biologics CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Biologics CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Biologics CDMO Sales Value (2021-2032) & (US$ Million) Figure 31. North America Biologics CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Biologics CDMO Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Biologics CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Biologics CDMO Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Biologics CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Biologics CDMO Sales Value (2021-2032) & (US$ Million) Figure 37. South America Biologics CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Biologics CDMO Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Biologics CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Biologics CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Biologics CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Biologics CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Biologics CDMO Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Biologics CDMO Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Biological Agent
  • Biosimilar Drug
Applications
  • Cell Therapy
  • Drug Development
  • Others
Companies covered
  • AGC
  • Boehringer Ingelheim
  • Fujifilm Diosynth Biotechnologies
  • ICON Plc
  • Samsung Biologics
  • Toyobo
  • AbbVie
  • Lonza Group AG
  • Thermo Fisher Scientific
  • WuXi Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biologics CDMO Sales Value (2021-2032)
  4. 1.2.2 Global Biologics CDMO Sales Volume (2021-2032)
  5. 1.2.3 Global Biologics CDMO Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Biologics CDMO Market Dynamics
  1. 2.1 Biologics CDMO Industry Trends
  2. 2.2 Biologics CDMO Industry Drivers
  3. 2.3 Biologics CDMO Industry Opportunities and Challenges
  4. 2.4 Biologics CDMO Industry Restraints
3 Biologics CDMO Market by Company
  1. 3.1 Global Biologics CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Biologics CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Biologics CDMO Sales Volume by Company (2021-2026)
  4. 3.4 Global Biologics CDMO Average Price by Company (2021-2026)
  5. 3.5 Global Biologics CDMO Company Ranking (2024-2026)
  6. 3.6 Global Biologics CDMO Company Manufacturing Base and Headquarters
  7. 3.7 Global Biologics CDMO Company Product Type and Application
  8. 3.8 Global Biologics CDMO Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Biologics CDMO Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Biologics CDMO Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Biologics CDMO Market by Type
  1. 4.1 Biologics CDMO Type Introduction
  2. 4.1.1 Biological Agent
  3. 4.1.2 Biosimilar Drug
  4. 4.2 Global Biologics CDMO Sales Volume by Type
  5. 4.2.1 Global Biologics CDMO Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Biologics CDMO Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Biologics CDMO Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Biologics CDMO Sales Value by Type
  9. 4.3.1 Global Biologics CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Biologics CDMO Sales Value by Type (2021-2032)
  11. 4.3.3 Global Biologics CDMO Sales Value Share by Type (2021-2032)
5 Biologics CDMO Market by Application
  1. 5.1 Biologics CDMO Application Introduction
  2. 5.1.1 Cell Therapy
  3. 5.1.2 Drug Development
  4. 5.1.3 Others
  5. 5.2 Global Biologics CDMO Sales Volume by Application
  6. 5.2.1 Global Biologics CDMO Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biologics CDMO Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Biologics CDMO Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Biologics CDMO Sales Value by Application
  10. 5.3.1 Global Biologics CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Biologics CDMO Sales Value by Application (2021-2032)
  12. 5.3.3 Global Biologics CDMO Sales Value Share by Application (2021-2032)
6 Biologics CDMO Regional Sales and Value Analysis
  1. 6.1 Global Biologics CDMO Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biologics CDMO Sales by Region (2021-2032)
  3. 6.2.1 Global Biologics CDMO Sales by Region: 2021-2026
  4. 6.2.2 Global Biologics CDMO Sales by Region (2027-2032)
  5. 6.3 Global Biologics CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Biologics CDMO Sales Value by Region (2021-2032)
  7. 6.4.1 Global Biologics CDMO Sales Value by Region: 2021-2026
  8. 6.4.2 Global Biologics CDMO Sales Value by Region (2027-2032)
  9. 6.5 Global Biologics CDMO Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Biologics CDMO Sales Value (2021-2032)
  12. 6.6.2 North America Biologics CDMO Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Biologics CDMO Sales Value (2021-2032)
  15. 6.7.2 Europe Biologics CDMO Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Biologics CDMO Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Biologics CDMO Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Biologics CDMO Sales Value (2021-2032)
  21. 6.9.2 South America Biologics CDMO Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Biologics CDMO Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Biologics CDMO Sales Value Share by Country, 2025 VS 2032
7 Biologics CDMO Country-level Sales and Value Analysis
  1. 7.1 Global Biologics CDMO Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biologics CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Biologics CDMO Sales by Country (2021-2032)
  4. 7.3.1 Global Biologics CDMO Sales by Country (2021-2026)
  5. 7.3.2 Global Biologics CDMO Sales by Country (2027-2032)
  6. 7.4 Global Biologics CDMO Sales Value by Country (2021-2032)
  7. 7.4.1 Global Biologics CDMO Sales Value by Country (2021-2026)
  8. 7.4.2 Global Biologics CDMO Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Biologics CDMO Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Biologics CDMO Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Biologics CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Biologics CDMO Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Biologics CDMO Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Biologics CDMO Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Biologics CDMO Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Biologics CDMO Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Biologics CDMO Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Biologics CDMO Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Biologics CDMO Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Biologics CDMO Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Biologics CDMO Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Biologics CDMO Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Biologics CDMO Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Biologics CDMO Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Biologics CDMO Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Biologics CDMO Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Biologics CDMO Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Biologics CDMO Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Biologics CDMO Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Biologics CDMO Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Biologics CDMO Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Biologics CDMO Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Biologics CDMO Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Biologics CDMO Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Biologics CDMO Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Biologics CDMO Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Biologics CDMO Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Biologics CDMO Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Biologics CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AGC
  2. 8.1.1 AGC Company Information
  3. 8.1.2 AGC Business Overview
  4. 8.1.3 AGC Biologics CDMO Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AGC Biologics CDMO Product Portfolio
  6. 8.1.5 AGC Recent Developments
  7. 8.2 Boehringer Ingelheim
  8. 8.2.1 Boehringer Ingelheim Company Information
  9. 8.2.2 Boehringer Ingelheim Business Overview
  10. 8.2.3 Boehringer Ingelheim Biologics CDMO Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Boehringer Ingelheim Biologics CDMO Product Portfolio
  12. 8.2.5 Boehringer Ingelheim Recent Developments
  13. 8.3 Fujifilm Diosynth Biotechnologies
  14. 8.3.1 Fujifilm Diosynth Biotechnologies Company Information
  15. 8.3.2 Fujifilm Diosynth Biotechnologies Business Overview
  16. 8.3.3 Fujifilm Diosynth Biotechnologies Biologics CDMO Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Fujifilm Diosynth Biotechnologies Biologics CDMO Product Portfolio
  18. 8.3.5 Fujifilm Diosynth Biotechnologies Recent Developments
  19. 8.4 ICON Plc
  20. 8.4.1 ICON Plc Company Information
  21. 8.4.2 ICON Plc Business Overview
  22. 8.4.3 ICON Plc Biologics CDMO Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 ICON Plc Biologics CDMO Product Portfolio
  24. 8.4.5 ICON Plc Recent Developments
  25. 8.5 Samsung Biologics
  26. 8.5.1 Samsung Biologics Company Information
  27. 8.5.2 Samsung Biologics Business Overview
  28. 8.5.3 Samsung Biologics Biologics CDMO Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Samsung Biologics Biologics CDMO Product Portfolio
  30. 8.5.5 Samsung Biologics Recent Developments
  31. 8.6 Toyobo
  32. 8.6.1 Toyobo Company Information
  33. 8.6.2 Toyobo Business Overview
  34. 8.6.3 Toyobo Biologics CDMO Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Toyobo Biologics CDMO Product Portfolio
  36. 8.6.5 Toyobo Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Biologics CDMO Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Biologics CDMO Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 Lonza Group AG
  44. 8.8.1 Lonza Group AG Company Information
  45. 8.8.2 Lonza Group AG Business Overview
  46. 8.8.3 Lonza Group AG Biologics CDMO Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Lonza Group AG Biologics CDMO Product Portfolio
  48. 8.8.5 Lonza Group AG Recent Developments
  49. 8.9 Thermo Fisher Scientific
  50. 8.9.1 Thermo Fisher Scientific Company Information
  51. 8.9.2 Thermo Fisher Scientific Business Overview
  52. 8.9.3 Thermo Fisher Scientific Biologics CDMO Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Thermo Fisher Scientific Biologics CDMO Product Portfolio
  54. 8.9.5 Thermo Fisher Scientific Recent Developments
  55. 8.10 WuXi Biologics
  56. 8.10.1 WuXi Biologics Company Information
  57. 8.10.2 WuXi Biologics Business Overview
  58. 8.10.3 WuXi Biologics Biologics CDMO Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 WuXi Biologics Biologics CDMO Product Portfolio
  60. 8.10.5 WuXi Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biologics CDMO Value Chain Analysis
  2. 9.1.1 Biologics CDMO Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biologics CDMO Sales Mode & Process
  6. 9.2 Biologics CDMO Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biologics CDMO Distributors
  9. 9.2.3 Biologics CDMO Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst